Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
LifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting
Related news for (DFFN)
- DIFFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Diffusion Pharmaceuticals Inc. – DFFN
- Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC